It was significant enough to stop the trial.
(http://www.ncbi.nlm.nih.gov/pubmed/19570573?dopt=Abstract)
> FINDINGS: At the second interim analysis, the hazard ratio for mortality in patients on interferon gamma-1b showed absence of minimum benefit compared with placebo (1.15, 95% CI 0.77-1.71, p=0.497), and indicated that the study should be stopped. After a median duration of 64 weeks (IQR 41-84) on treatment, 80 (15%) patients on interferon gamma-1b and 35 (13%) on placebo had died. Almost all patients reported at least one adverse event, and more patients on interferon gamma-1b group had constitutional signs and symptoms (influenza-like illness, fatigue, fever, and chills) than did those on placebo. Occurrence of serious adverse events (eg, pneumonia, respiratory failure) was similar for both treatment groups. Treatment adherence was good and few patients discontinued treatment prematurely in either group.
"That was the death knell for the drug. Most insurers stopped paying for it."
I don't think they're implying that the drug killed people. I think they're saying that the study made it obvious it wasn't helping, so insurers stopped covering it and other consequences followed.